Phase 2 N=131 Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Cutaneous T Cell Lymphoma · Peripheral T Cell Lymphoma
Primary: Number of Participants With a Response — 17; 28; 8; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=12 Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
Phase 2 N=37 Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Median Progression-free Survival — 5 months
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=14 Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg
Phase 2 N=18 Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Cutaneous Leiomyomas · Hereditary Leiomyomatosis and Renal Cell Cancer
Primary: Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory — -2.50; -1.26 units on a scale
Phase 2 N=10 Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=77 Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Peripheral T Cell Lymphoma · PTCL · Extranodal NK/T-cell Lymphoma
Primary: Overall Response Rate (ORR) — 31.8; 20.5; 45.5 Percentage of participants
Phase 4 N=10 Short-term B-cell Depletion in Relapsing Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants
Phase 1 N=11 Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Primary: MTD of Photodynamic Therapy — 150 J/cm^2
Phase 3 N=131 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Primary Cutaneous Anaplastic Large Cell Lymphoma · Mycosis Fungoides · Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) — 54.7; 12.5 percentage of participants — p=<0.001
N/A N=41 A Research Study to Examine Cutaneous Allodynia and Cluster Headache
Cluster Headache
Primary: Prevalence of Allodynia in Subjects With Cluster Headache — 20 participants
Phase 1 N=38 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
Hodgkin's Disease · Non-Hodgkin's Lymphoma
Primary: The Maximum Tolerated Dose (MTD) of Niacinamide in the Combination of Vorinostat and Niacinamide — 100 mg/kg